NASDAQ, TSX: NVCN Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results VANCOUVER and MINNEAPOLIS, March 30, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the TiaraTM (“Tiara”), and minimally...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, March 17, 2020 – Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter...
Read MoreVANCOUVER, March 4, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, recaps the presentation by CEO Fred Colen at the...
Read MoreStudies demonstrate the Neovasc Reducer™ alleviates refractory angina symptoms NASDAQ, TSX: NVCN VANCOUVER, March 4, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, February 20, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, February 14, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, February 12, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Read MoreNASDAQ, TSX: NVCN Vancouver, Canada, February 11, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced...
Read More